Compare Citius Pharmaceuticals Inc (CTXR) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Alphabet Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Alphabet Inc Class A trades at $365.18 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 298497.3× Citius Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GOOGL | |
|---|---|---|
Market Cap | $14.64M | $4.37T |
Sector | Health | Media |
52-Week High | $1.82 | $402.62 |
52-Week Low | $0.53 | $182.00 |
Enterprise Value | $10.86M | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Alphabet (GOOGL) trades at $361.93, up 2.67% today, with a neutral technical signal but bullish moving averages. The company reported strong Q1 2026 earnings of $5.11 EPS, beating estimates, and maintains robust profitability with a 37.92% net margin. Recent news highlights AI-driven growth opportunities through partnerships and YouTube price increases.
Outlook remains positive with 85% analyst buy ratings and a $431.78 consensus target, though risks include antitrust scrutiny and tech sector volatility. Revenue growth and AI integration present key upside catalysts for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
